- Home
- HRB vs ROIV Comparison
HRB vs ROIV Comparison
Compare HRB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRB
- ROIV
- Stock Information
- Founded
- HRB 1955
- ROIV 2014
- Country
- HRB United States
- ROIV United Kingdom
- Employees
- HRB N/A
- ROIV N/A
- Industry
- HRB Other Consumer Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- HRB Consumer Discretionary
- ROIV Health Care
- Exchange
- HRB Nasdaq
- ROIV Nasdaq
- Market Cap
- HRB 8.2B
- ROIV 8.4B
- IPO Year
- HRB N/A
- ROIV N/A
- Fundamental
- Price
- HRB $57.68
- ROIV $10.79
- Analyst Decision
- HRB Sell
- ROIV Buy
- Analyst Count
- HRB 2
- ROIV 4
- Target Price
- HRB $62.00
- ROIV $17.50
- AVG Volume (30 Days)
- HRB 1.7M
- ROIV 5.9M
- Earning Date
- HRB 05-07-2025
- ROIV 05-29-2025
- Dividend Yield
- HRB 2.60%
- ROIV N/A
- EPS Growth
- HRB N/A
- ROIV N/A
- EPS
- HRB 4.04
- ROIV N/A
- Revenue
- HRB $3,712,614,000.00
- ROIV $122,585,000.00
- Revenue This Year
- HRB $4.20
- ROIV N/A
- Revenue Next Year
- HRB $2.74
- ROIV N/A
- P/E Ratio
- HRB $14.25
- ROIV N/A
- Revenue Growth
- HRB 3.71
- ROIV 140.04
- 52 Week Low
- HRB $48.23
- ROIV $8.73
- 52 Week High
- HRB $68.45
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- HRB 46.46
- ROIV 50.06
- Support Level
- HRB $55.54
- ROIV $10.58
- Resistance Level
- HRB $64.62
- ROIV $11.77
- Average True Range (ATR)
- HRB 1.77
- ROIV 0.34
- MACD
- HRB -0.65
- ROIV -0.07
- Stochastic Oscillator
- HRB 23.57
- ROIV 17.65
About HRB H&R Block Inc.
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.